The medical community is rapidly trying to identify complications and patterns of disease to improve patient outcomes as the COVID-19 pandemic continues.

Numerous studies have shown varying degrees of liver damage in patients with COVID-19.

Recently published studies have reported that the incidence of liver injury ranged from 14.8% to 53% in patients diagnosed with COVID-19 as determined by abnormal alanine transaminase and aspartate transaminase levels accompanied by elevated bilirubin levels.

Read More